Northwire Canada EditionWednesday, July 15, 2026
Northwire
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%
Production / Operations

Telescope Innovations Installs Second Self-Driving Lab at Pfizer

TELI · Price

Executive Summary

  • Telescope Innovations installed its second Self‑Driving Laboratory (SDL) at Pfizer, completing the installation in January 2026.
  • The SDL is a fixed‑position Physical AI platform that automates chemical experimentation using robotics, real‑time analytics and machine‑learning‑guided design, promising up to 100× faster development cycles.
  • Management highlighted the partnership with Pfizer as a key milestone toward broader commercial deployment and cost‑saving potential for drug development.

Key Details

  • Installation Milestone: Second SDL deployed at Pfizer; marks transition from collaborative R&D to possible full‑scale rollout.
  • Technology Overview: Fixed‑position Physical AI platform integrating collaborative robotics, Process Analytical Technology (PAT), and machine‑learning‑driven experimental design in a continuous, autonomous closed‑loop workflow.
  • Performance Claims: Capable of 24/7 operation across multiple reaction vessels; accelerates chemical synthesis development up to 100× versus traditional manual methods.
  • Potential Benefits: Significant reduction in drug development timelines and cost savings; enables faster market entry for new innovations.
  • Management Commentary: CEO Henry Dubina emphasized the partnership’s strength and anticipated cost‑saving impact; CTO Dr. Jason Hein noted the platform’s transferability to other domains requiring rapid chemical or material process optimization.

Notable Quotes

“The installation of our second SDL at one of the world's largest pharmaceutical companies is a testament to the strength of our ongoing partnership with Pfizer… could enable the acceleration of new innovations into the market.” – Henry Dubina, CEO

“With this second SDL deployment, we are pleased to continue demonstrating Physical AI at work… the core closed‑loop architecture is directly transferable to any domain that requires rapid optimization of chemical or materials processes.” – Dr. Jason Hein, Founder & CTO

Read the original news release →

More from Telescope Innovations Corp.